Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wineke Armbrust

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Rheumatology (Oxford, England)|May 15, 2025
Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacySaskia R Veldkamp, Maud Reugebrink, Sanne W Evers, et al.
Rheumatology (Oxford, England)|December 26, 2012
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Marieke H Otten, Femke H M Prince, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Rheumatology (Oxford, England)|June 7, 2013
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Marieke H Otten, Simone L Gorter, et al.
JAMA|April 8, 2010
Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trialDirk Foell, Nico Wulffraat, Lucy R Wedderburn, et al.
The Pediatric Infectious Disease Journal|October 12, 2023
Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children From Wild-type to Population Immunity: A Prospective Multicenter Cohort Study With Real-time ReportingAdam J Tulling, Gertjan Lugthart, Miriam G Mooij, et al.
Pediatric Rheumatology Online Journal|September 17, 2018
Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocolCasper G Schoemaker, Wineke Armbrust, Joost F Swart, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 13, 2019
Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort ValidationJudith Wienke, Felicitas Bellutti Enders, Johan Lim, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Annals of the Rheumatic Diseases|June 26, 2012
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterMarieke H Otten, Femke H M Prince, Janneke Anink, et al.
Rheumatology (Oxford, England)|May 15, 2025
Targeting interferon responses in juvenile dermatomyositis: Siglec-1 as an in vitro biomarker for JAK inhibitor efficacySaskia R Veldkamp, Maud Reugebrink, Sanne W Evers, et al.
Rheumatology (Oxford, England)|December 26, 2012
Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children RegisterJanneke Anink, Marieke H Otten, Femke H M Prince, et al.
Annals of the Rheumatic Diseases|March 20, 2014
Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children RegisterMarieke H Otten, Janneke Anink, Femke H M Prince, et al.
Rheumatology (Oxford, England)|June 7, 2013
Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?Janneke Anink, Marieke H Otten, Simone L Gorter, et al.
JAMA|April 8, 2010
Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trialDirk Foell, Nico Wulffraat, Lucy R Wedderburn, et al.
The Pediatric Infectious Disease Journal|October 12, 2023
Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children From Wild-type to Population Immunity: A Prospective Multicenter Cohort Study With Real-time ReportingAdam J Tulling, Gertjan Lugthart, Miriam G Mooij, et al.
Pediatric Rheumatology Online Journal|September 17, 2018
Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocolCasper G Schoemaker, Wineke Armbrust, Joost F Swart, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 13, 2019
Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort ValidationJudith Wienke, Felicitas Bellutti Enders, Johan Lim, et al.
Pageof 5